Search results for "Conservation"

showing 10 items of 2328 documents

Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: Similarities with phossy jaw.

2013

Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term side effects BP, a form of avascular osteonecrosis of the jaw has been reported. Although, invasive oral local procedures are often present in clinical history of patients suffering from bisphosphonates-related osteonecrosis of the jaws (BRONJ), about up to 50% of BRONJ are spontaneous. We report a case of a 68-year-old female with a spontaneous wide bone sequestration of the left mandibular body onset after infusion of zoledronic acid for 18 cycles for osseous metastasis due to metastatic anaplastic thyroidal carcinoma. Surprisingly the clinical aspects of the patient initially reminded us …

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsZoledronic AcidBone sequestrationstomatognathic systemMandibular bodySettore MED/28 - Malattie OdontostomatologichemedicineCarcinomaHumansMandibular DiseasesThyroid Neoplasmsthyroidal carcinomaGeneral DentistryAgedPhossy jawBone Density Conservation AgentsDiphosphonatesbusiness.industryCarcinomaMandibleImidazolesBisphosphonatesGeneral MedicineBisphosphonatemedicine.diseaseBisphosphonatesbisphosphonates‑related osteonecrosis of the jaws thyroidal carcinoma zoledronic acidbisphosphonates-related osteonecrosis of the jawsSurgerylcsh:RK1-715stomatognathic diseasesZoledronic acidlcsh:DentistryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugFollow-Up Studies
researchProduct

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents

2015

Background The clinical management of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with bisphosphonates and other antiresorptive agents is subject to controversy. The American Association of Oral and Maxillofacial Surgeons (AAOMS) has developed guidelines for the correct management of the disorder which are revised and updated by a panel of experts. Material and Methods The present systematic review analyzes the different treatments currently used to treat this clinical condition, based on the PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement published in 2009. An electronic Medline search was made of the PubMed database, cover…

medicine.medical_specialtyMEDLINEAlternative medicineDentistryDiseaseReview03 medical and health sciences0302 clinical medicineAntiresorptive AgentsmedicineHumansStage (cooking)Intensive care medicineGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngology030220 oncology & carcinogenesisTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jaw
researchProduct

Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized tri…

2005

Little is known about the relative effectiveness of calcium supplementation from food or pills with or without vitamin D supplementation for bone mass accrual during the rapid growth period.The purpose was to examine the effects of both food-based and pill supplements of calcium and vitamin D on bone mass and body composition in girls aged 10-12 y.This placebo-controlled intervention trial randomly assigned 195 healthy girls at Tanner stage I-II, aged 10-12 y, with dietary calcium intakes900 mg/d to 1 of 4 groups: calcium (1000 mg) + vitamin D3 (200 IU), calcium (1000 mg), cheese (1000 mg calcium), and placebo. Primary outcomes were bone indexes of the hip, spine, and whole body by dual-ene…

medicine.medical_specialtyMedicine (miscellaneous)chemistry.chemical_elementCalciumBone remodelinglaw.inventionchemistry.chemical_compoundAbsorptiometry PhotonRandomized controlled trialDouble-Blind MethodlawBone DensityCheeseInternal medicinemedicineVitamin D and neurologyHumansVitamin DChildMenarcheAnalysis of VarianceNutrition and DieteticsIntention-to-treat analysisBone DevelopmentBone Density Conservation AgentsTibiabusiness.industryPubertyCalcium DietaryRadiusEndocrinologymedicine.anatomical_structurechemistryPillDietary SupplementsBody CompositionLinear ModelsPatient ComplianceCortical boneFemaleBone RemodelingDairy ProductsbusinessCholecalciferol
researchProduct

Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)

2012

Dear Editor, It is the authors’ belief that the internationally accepted definition of bisphosphonate-related osteonecrosis of the jaws (BRONJ) (Ruggiero et al, 2009) has several limitations that prevent clinicians from being confident with the diagnosis of the disease. Following recognition of the non-exposed BRONJ clinical variant (Lazarovici et al, 2009), we all became aware that the presence of ‘exposed necrotic bone in the oral cavity’, as outlined in the American Association of Oral and Maxillofacial Surgery (AAOMS) case definition, is just one of the possible clinical manifestations of BRONJ and is not found in all BRONJ patients. As ‘bone exposure’ is certainly not the initial sign …

medicine.medical_specialtyMedullary cavityBone diseaseBiopsymedicine.medical_treatmentSettore MED/29 - Chirurgia MaxillofaccialeDiagnosis DifferentialSettore MED/28 - Malattie OdontostomatologicheTerminology as TopicOral and maxillofacial pathologymedicineHumansGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryDecision TreesBisphosphonatemedicine.diseaseSurgeryOtorhinolaryngologybisphosphonate-related osteonecrosis of the jawOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawDifferential diagnosisOsteonecrosis of the jawbusiness
researchProduct

Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.

2015

A previous animal study compared the nephrotoxic effect of ibandronate (IBN) and zoledronate (ZOL), but interpretation of these study results was limited because of the model of minimal nephrotoxic dosage with a dosage ratio of 1:3. The present study investigated the nephrotoxicity of ibandronate and zoledronate in a 1.5:1 dose ratio, as used in clinical practice and compared the nephrotoxicity in rats with normal and with mildly to moderately impaired renal function. We compared rats with normal renal function (SHAM) and with impaired renal function after unilateral nephrectomy (UNX), treated either with ibandronate 1.5mg/kg, zoledronate 1mg/kg or placebo once (1×) or nine (9×) times. Rena…

medicine.medical_specialtyNecrosisMedullary cavitymedicine.medical_treatmentRenal functionPlaceboKidneyNephrectomyZoledronic AcidNephrotoxicityInternal medicinemedicineAnimalsHumansRenal InsufficiencyRats WistarIbandronic AcidPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesUnilateral nephrectomyBisphosphonateRatsEndocrinologyToxicityFemalemedicine.symptombusinessPharmacological research
researchProduct

Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia.

2019

Objective Subcutaneous fat necrosis (SCFN) is a rare condition that may occur in the neonatal period. SCFN is an inflammatory disorder of the adipose tissue, usually found in full-term healthy infants who have a history of intrauterine or perinatal distress. It is usually a self-limited condition; however, in some cases, it can get complicated, leading to severe hypercalcemia that may be life-threatening. Study Design We report and describe a classic presentation of SCFN that led to severe hypercalcemia refractory to standard treatment. The diagnosis of SCFN was made based on the finding of subcutaneous nodules and of hypercalcemia. The serum calcium level reached 16.6 mg/dL. Hypercalcemia…

medicine.medical_specialtyNecrosisTerm BirthDrug ResistanceSubcutaneous FatAdipose tissuehypercalcemia; neonate; subcutaneous fat necrosis; zoledronic acid; Bone Density Conservation Agents; Calcium; Drug Resistance; Fat Necrosis; Female; Furosemide; Glucocorticoids; Humans; Hypercalcemia; Infant Newborn; Methylprednisolone; Sodium Potassium Chloride Symporter Inhibitors; Subcutaneous Fat; Term Birth; Zoledronic AcidGastroenterologyMethylprednisoloneZoledronic AcidRefractorySodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinesubcutaneous fat necrosismedicineHumansFat necrosisFat NecrosisGlucocorticoidsBone Density Conservation Agentsbusiness.industryStandard treatmentInfant NewbornObstetrics and GynecologyFurosemideInfantmedicine.diseaseNewbornZoledronic acidMethylprednisolonePediatrics Perinatology and Child HealthHypercalcemiaCalciumFemalemedicine.symptomneonatebusinessmedicine.drugAmerican journal of perinatology
researchProduct

Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparat…

2013

Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied during the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 Ruggiero classification and absence of…

medicine.medical_specialtyOdontologíaPilot ProjectsGroup AGroup BFibrinTeriparatidemedicineTeriparatideHumansStage (cooking)General DentistryAgedAged 80 and overFibrinBisphosphonate-associated osteonecrosis of the jawOral bisphosphonatesOral Medicine and PathologybiologyBone Density Conservation Agentsbusiness.industryResearchMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASbiology.proteinIntercellular Signaling Peptides and ProteinsSurgeryPrimary osteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemalebusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Effect of 2 years of endurance and high-impact training on preventing osteoporosis in postmenopausal women: randomized clinical trial.

2018

The aim of the study was to analyze the effects of endurance and high-impact training oriented toward preventing osteoporosis in postmenopausal women with calcium and vitamin D supplementation.This study was a randomized clinical trial. Thirty-six postmenopausal women were randomized to the control and experimental groups. Thirty-four women completed the 2-year interventions. The control group training involved walking at an intense pace. The experimental group conducted high-impact training specifically oriented to prevent osteoporosis. Dual-energy x-ray absorptiometry was used to estimate the T-scores of the lumbar spine and femoral neck.The fast-walking group showed constant T-scores in …

medicine.medical_specialtyOsteoporosis030209 endocrinology & metabolismWalkinglaw.invention03 medical and health sciences0302 clinical medicineAbsorptiometry PhotonRandomized controlled triallawBone DensitymedicineVitamin D and neurologyHumansVitamin DOsteoporosis PostmenopausalPostmenopausal womenLumbar VertebraeBone Density Conservation Agentsbusiness.industryFemur NeckObstetrics and GynecologyMiddle Agedmedicine.diseaseCalcium DietaryPostmenopauseEndurance TrainingPhysical therapyFemalebusiness030217 neurology & neurosurgeryMenopause (New York, N.Y.)
researchProduct

Alendronate-associated osteonecrosis of the jaws: a review of the main topics

2013

Bisphosphonates is a group of inorganic pyrophosphates analogues that suppress bone resorption by inducing osteoclast inactivation, being frequently used for management of diseases affecting bone metabolism, bone metastases and bone tumors. However, since 2003 many cases describing the presence of necrotic bone exposures in the jaws have been described in patients receiving these drugs, what represent a significant complication of bisphosphonates treatment. The overall incidence of bisphosphonate-related osteonecrosis of the jaws is low, ranging from 0.7% to 12%, mainly observed in those patients receiving intravenously treatment. Osteonecrosis of the jaws associated to oral bisphosphonate,…

medicine.medical_specialtyOsteoporosisOdontologíaReviewBone resorptionBone remodelingOsteoclastmedicineHumansIn patientGeneral DentistryPathologicalOral Medicine and PathologyAlendronateBone Density Conservation Agentsbusiness.industryNecrotic bonemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgerymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawComplicationbusiness
researchProduct

Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.

2013

Osteoporosis is characterized by low bone mineral density and/or poor bone microarchitecture leading to an increased risk of fractures. The skeletal alterations in osteoporosis are a consequence of a relative deficit of bone formation compared to bone resorption. Osteoporosis therapies have mostly relied on antiresorptive drugs. An alternative therapeutic approach for osteoporosis is currently available, based on the intermittent administration of parathyroid hormone (PTH). Bone anabolism caused by PTH therapy is mainly accounted for by the ability of PTH to increase osteoblastogenesis and osteoblast survival. PTH and PTH-related protein (PTHrP)-an abundant local factor in bone- interact wi…

medicine.medical_specialtyOsteoporosisParathyroid hormoneBone healingBiochemistryBone resorptionBone remodelingOsteogenesisInternal medicinemedicineAnimalsHumansBone regenerationCell ProliferationReceptor Parathyroid Hormone Type 1PharmacologyBone mineralOsteoblastsBone Density Conservation Agentsbusiness.industryParathyroid Hormone-Related ProteinOsteoblastCell Differentiationmedicine.diseaseProtein Structure Tertiarymedicine.anatomical_structureEndocrinologyGene Expression RegulationParathyroid HormoneOsteoporosisFemalebusinesshormones hormone substitutes and hormone antagonistsSignal TransductionBiochemical pharmacology
researchProduct